Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer

被引：0
|
作者：
Gomez, HL
Chavez, MA
Doval, DC
Nag, S
Chow, LW
Ang, PC
Ahmad, NM
Berger, M
Newstat, B
Stein, S
Sledge, GW
机构：
[1] Inst Especializado Enfermedades Neoplas, Lima, Peru
[2] Hosp Alberto Sabogal, Lima, Peru
[3] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India
[4] Jehangir Hosp & Med Ctr, Pune, Maharashtra, India
[5] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Natl Canc Ctr, Singapore, Singapore
[7] Univ Hosp, Bharu, Kalatan, Malaysia
[8] GlaxoSmithKline Inc, Collegeville, PA USA
[9] Indiana Univ, Indianapolis, IN 46204 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [21] A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.
    Blackwell, KL
    Kaplan, EH
    Franco, SX
    Marcom, PK
    Maleski, JE
    Sorensen, MJ
    Berger, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 196S - 196S
  • [22] Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Possinger, K
    Kaufmann, M
    Coleman, R
    Stuart, NSA
    Helsing, M
    Ohnmacht, U
    Arning, M
    ANTI-CANCER DRUGS, 1999, 10 (02) : 155 - 162
  • [23] Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study
    de la Haba-Rodriguez, Juan
    Gonzalez Mancha, Rosario
    Perez Manga, Gumersindo
    Aranda Aguilar, Enrique
    Baena Canada, Jose Manuel
    Sanchez Rovira, Pedro
    Alba Conejo, Emilio
    CLINICAL BREAST CANCER, 2010, 10 (04) : 313 - 317
  • [24] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [25] Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer
    Hoelzer, K. L.
    Brufsky, A.
    Hainsworth, J.
    Beck, J. T.
    Whorf, R.
    Keaton, M.
    Kroener, J.
    Krill-Jackson, E.
    Hu, S.
    Bromund, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
    Gomez, H. L.
    Chavez, M. A.
    Doval, D. C.
    Franco, S.
    Arbushites, M.
    Berger, M. S.
    Casey, M. A.
    Stein, S.
    Zaks, T.
    Martin, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Biomarker analysis of lapatinib with paclitaxel versus paclitaxel as first-line treatment in 580 patients with metastatic breast cancer
    Finn, R. S.
    Press, M. F.
    Dering, J.
    Gomez, H.
    Aziz, Z.
    Arbushites, M.
    Koehler, M.
    Oliva, C.
    Williams, L. S.
    Di Leo, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 212 - 212
  • [28] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    E van Meerten
    F A L M Eskens
    E C van Gameren
    L Doorn
    A van der Gaast
    British Journal of Cancer, 2007, 96 : 1348 - 1352
  • [29] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    van Meerten, E.
    Eskens, F. A. L. M.
    van Gameren, E. C.
    Doorn, L.
    van der Gaast, A.
    BRITISH JOURNAL OF CANCER, 2007, 96 (09) : 1348 - 1352
  • [30] A single arm, multicentre, open-label phase II study of orally administered lapatinib (GW572016) as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
    Grimm, MO
    Machiels, JP
    Wülfing, C
    Richel, D
    Treiber, U
    de Groot, M
    Beuzeboc, P
    Farrell, J
    Colman, J
    El-Hariry, I
    ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41
12345